Invisalign trailblazes a path direct to the consumer| A conversation with Align Technology CEO Tom Prescott

November 28, 2012 by Brian Johnson

In this MassDevice Big 100 West preview we talk to Align Technology CEO Tom Prescott about how Invisalign crossed the chasm into mainstream culture through social media and aggressive consumer marketing strategies.

Align Technology CEO Tom Prescott

Crooked-toothed teens may want to consider sliding a picture of Tom Prescott next to that fading "Twilight" poster on the wall.

The CEO of Align Technology (NSDQ:ALGN) may not be as dreamy as Edward the vampire, but the head of the Sunnyvale, Calif.-based maker of Invisalign invisible braces is doing his best to free teens from the tyranny of the wire-and-bracket braces that have dominated the world of orthontistry for more than a century.

Disrupting the dental industry isn't easy, Prescott told But Align has aggressively grown into a clear market force in the industry, with more than 2 million Invisalign products on the market and about $500 million in annual sales, in part through 1 of the most aggressive direct-to-consumer campaigns ever seen in medtech. The result? Prospective patients are asking their dentists for Invisalign by name.

We sat down with Prescott recently, in advance of his appearance at the MassDevice Big 100 West Dec. 11 in Newport Beach, Calif., to talk about how Align's sales & marketing model works and explore how the lessons embedded there could be applied to the medical device space.

Interested in hearing more in person? Register here to join us Dec. 11 Is the dental industry facing the same problems as the device industry, in terms of uncertainty around its business model?

Tom Prescott: The dental industry is mostly private-pay, with patients paying out-of-pocket plus pre-paid insurance through a Delta or 1 of the other big providers. It's not capitated insurance, like the Kaisers of the world. People are used to paying for part of, or sometimes all of, their procedures.



David Green tells about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years. brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at's DeviceTalks Boston event.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp